Genmab A/S (NASDAQ:GMAB) Short Interest Up 40.0% in February

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,310,000 shares, an increase of 40.0% from the February 13th total of 1,650,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.4% of the shares of the stock are short sold.

Genmab A/S Trading Down 2.9 %

GMAB stock traded down $0.60 during mid-day trading on Tuesday, hitting $20.20. The stock had a trading volume of 1,747,434 shares, compared to its average volume of 907,876. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.02. The company has a fifty day moving average of $21.18 and a 200 day moving average of $22.28. The stock has a market capitalization of $13.37 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. Barclays PLC increased its holdings in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC increased its holdings in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after acquiring an additional 2,496 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GMAB. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Finally, Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.